The issue is that L requires help controlling the signaling in the tumor microenvironment because DC sentinels are not there actively managing the immune response. That’s not an issue with Direct when proper spacing of treatments is done. The SPORE project is just trying to catch up to what Direct already does. The issue for Direct is managing the pace of the immune response in an enclosed environment where pressure from immune cell infiltration can mount quickly. This is something that can be effectively dealt with but “the process” keeps all of this from advancing more quickly and changing patient outcomes for the better. Can’t upset the status quo too quickly or the economic impact would disrupt financial stability for too many people or so goes the claim. You know all about that right?; ). Best wishes.
Market Data 
Markets 
AI
